Testing zanzalintinib for progressive pheochromocytoma or paraganglioma
Treatments studied
Part of Cancer clinical trials.
This trial tests an oral drug called zanzalintinib in people with pheochromocytoma or paraganglioma that has spread or cannot be removed by surgery and has gotten worse. The goal is to see if the drug can slow or stop tumor growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with pheochromocytoma or paraganglioma that has spread or cannot be surgically removed, and it has grown in the last year.
- You have at least one tumor that can be measured on a CT scan or MRI.
- You are generally able to care for yourself (ECOG performance status 0-2).
- Your kidney, liver, and blood cell counts are within acceptable ranges based on blood tests.
- You agree to use effective birth control during the study and for 4 months after the last dose.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs (anlotinib, a targeted therapy, and benmelstobart, an immunotherapy) for people with advanced pheochromocytoma or paraganglioma that cannot be removed by surgery. The goal is to see if this new combination can shrink tumors or stop them from growing when other treatments are not an option.
This trial tests a new drug called zanzalintinib for people with advanced or metastatic bone sarcomas that have not responded to standard treatments. It aims to see if the drug can help shrink or slow the growth of these tumors.
This trial studies an experimental drug called zanzalintinib for people with adenoid cystic carcinoma that has spread or come back. The goal is to see if the drug can shrink tumors or slow the disease.
This trial tests a new drug, zanzalintinib, in men with a fast-growing type of prostate cancer that has spread and stopped responding to standard hormone therapies. It aims to see if the drug can help shrink tumors or slow the disease.
This trial is looking at whether a new combination of two drugs, zanzalintinib and pembrolizumab, can help people with certain types of advanced soft-tissue sarcoma that have not responded to other treatments. It aims to find out if the combination is safe and effective.
This study tests a new drug called zanzalintinib in men with advanced prostate cancer (metastatic castration-resistant prostate cancer) who have already received Pluvicto treatment. The goal is to see if this drug can help slow or stop cancer growth when other hormone therapies are no longer working.
Hear when a new Pheochromocytoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.